IDEXX Laboratories, Inc. — Form 10-Q Summary
Business context and reporting period
Quarterly report for the three and nine months ended September 30, 2014. IDEXX operates through Companion Animal Group (CAG) veterinary diagnostics and information systems, Water, Livestock, Poultry and Dairy (LPD), and Other businesses. The filing was signed October 24, 2014.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $383.5 million | $338.3 million | $1,133.8 million | $1,023.0 million |
| Gross profit / margin | $213.3 million / 55.6% | $185.8 million / 54.9% | $634.0 million / 55.9% | $567.5 million / 55.5% |
| Operating income / margin | $72.2 million / 18.8% | $65.5 million / 19.4% | $225.5 million / 19.9% | $205.4 million / 20.1% |
| Net income attributable to IDEXX | $52.1 million | $45.7 million | $155.9 million | $144.5 million |
| Diluted EPS | $1.03 | $0.86 | $3.03 | $2.66 |
| Net cash from operations | Not provided for quarter | Not provided for quarter | $208.5 million | $180.6 million |
- Q3 revenue increased 13.4%; reported organic revenue growth was 12.8%. Nine-month revenue increased 10.8%, with 10.0% organic growth.
- CAG generated Q3 revenue of $320.7 million, up 13.0%, led by recurring diagnostics revenue, VetLab consumables and reference laboratory services. Nine-month CAG revenue was $949.0 million, up 10.8%.
- Q3 operating income rose 10.2%, but operating margin declined 60 basis points because of sales-transition costs and higher operating expenses. Excluding approximately $4.8 million of transition costs, adjusted Q3 operating income was approximately $76.9 million, or 20.1% of revenue.
- Effective tax rates were 23.5% in Q3 and 28.0% for the nine months, compared with 29.1% and 28.9%, respectively, in the prior-year periods. Benefits included lower international tax rates, tax-audit resolutions and a non-recurring intercompany-profit adjustment.
- Cash and cash equivalents were $292.7 million at September 30, 2014, versus $279.1 million at December 31, 2013. Working capital was $72.4 million versus $174.4 million at year-end.
- Cash used in investing activities was $44.8 million, including $42.5 million of capital expenditures and $7.5 million for acquisitions. The 2014 capital expenditure plan was approximately $75 million.
- Cash used in financing activities was $145.8 million, including $469.0 million of share repurchases, partially offset by $200.0 million of long-term debt issuance and $98.0 million of net revolving-facility borrowings.
Debt, liquidity and capital allocation
- The company had $375.0 million outstanding under a $700 million unsecured revolving credit facility maturing June 18, 2019, leaving approximately $324.0 million of borrowing availability after a $1.0 million letter of credit.
- Long-term debt was $350.0 million, including $200.0 million issued during 2014. Total debt was approximately $725.0 million, excluding other immaterial debt items.
- Credit-facility and senior-note agreements require a consolidated leverage ratio no greater than 3.5-to-1. IDEXX stated that it was in compliance with all debt covenants at September 30, 2014.
- The company repurchased 3.7 million shares for $469.0 million during the first nine months, compared with 3.1 million shares for $282.9 million in the prior-year period. No cash dividends have been paid or are currently intended.
- Management stated that cash, operating cash flow and available borrowings should be sufficient for operations, capital requirements and strategic growth needs for at least the next twelve months.
Material changes versus the prior comparable period
- Revenue growth was broad-based, with Q3 increases in CAG of 13.0%, Water of 10.8%, LPD of 18.0% and Other of 21.9%.
- Gross margin improved by 70 basis points in Q3 and 40 basis points for the nine months, primarily from product costs, pricing, manufacturing efficiencies and mix.
- Interest expense increased to $4.3 million in Q3 and $10.0 million for the nine months, versus $1.5 million and $3.5 million, respectively, due to additional senior notes.
- Share count declined materially from the prior year because of repurchases; diluted weighted-average shares fell to 50.4 million in Q3 from 53.2 million.
- The company refinanced and expanded its revolving credit facility, issued $200 million of additional long-term debt, acquired two small businesses, and divested a veterinary-hospital investment for $5.4 million, recognizing a $0.7 million gain.
- Prior-period cash-flow amounts were revised to correctly reflect $0.9 million of non-cash investing activity; management stated the error was not material.
Guidance, outlook, risks and unusual items
- IDEXX planned to move U.S. rapid-assay kits and instrument consumables to an all-direct sales model beginning January 1, 2015. Management expects approximately $50 million to $55 million of annual incremental revenue and approximately $5 million to $8 million of annual operating-profit benefit in 2015, with benefits scaling over time.
- For 2014, management expected approximately $6 million of incremental sales and operating-resource expense and $10 million to $12 million of non-recurring transition expense. Distributor inventory drawdown was expected to reduce Q4 revenue by $18 million to $23 million and operating profit by $15 million to $19 million, with limited potential carryover into Q1 2015.
- The transition may require approximately $15 million to $20 million of additional working capital. Three previously exclusive U.S. distributors announced plans to carry competing products before the transition was complete, increasing execution and customer-retention risk.
- Management expected lower European bovine-testing volumes in 2015 because of eradication programs and changes in BSE testing requirements.
- Foreign-exchange movements, economic conditions affecting veterinary spending and capital purchases, distributor inventory levels, competition, patent expirations, and regulatory and legal matters remain relevant risks. Management did not expect current legal proceedings to have a material effect, but noted that outcomes cannot be predicted with certainty.
- New revenue-recognition guidance was issued in 2014 and is effective for IDEXX beginning January 1, 2017. The company had not determined its adoption method or the financial-statement impact.
- Foreign-currency translation reduced other comprehensive income by $19.0 million in Q3 and $15.5 million for the nine months, partly offset by derivative gains.
Important facts for investors to verify
- Whether the all-direct U.S. sales transition achieves the projected $50 million to $55 million revenue opportunity without greater-than-estimated distributor destocking, customer losses or working-capital needs.
- Progression of debt leverage, interest expense and covenant headroom following the $350 million of senior-note issuance and increased revolving borrowings.
- Underlying CAG recurring-revenue growth excluding distributor inventory effects, pricing, acquisitions and foreign exchange.
- Sustainability of the lower effective tax rate, including the non-recurring tax benefit and expired U.S. R&D tax credit.
- Capital-allocation priorities, including the pace and funding of share repurchases relative to debt and operating cash flow.
- Implementation of the 2017 revenue-recognition standard and any effect on deferred revenue, contract costs and reported revenue timing.